Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $10.00

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have been given an average recommendation of "Hold" by the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

A number of brokerages have issued reports on ZNTL. Oppenheimer reissued an "outperform" rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Guggenheim dropped their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Finally, Wedbush upgraded shares of Zentalis Pharmaceuticals from an "underperform" rating to a "neutral" rating and set a $4.00 price target on the stock in a report on Monday, August 12th.

Zentalis Pharmaceuticals Trading Down 0.6 %

Shares of Zentalis Pharmaceuticals stock traded down $0.02 during mid-day trading on Friday, hitting $3.61. 423,855 shares of the stock were exchanged, compared to its average volume of 1,315,910. The company has a 50-day simple moving average of $3.38 and a 200 day simple moving average of $4.93. The stock has a market capitalization of $257.25 million, a price-to-earnings ratio of -1.48 and a beta of 1.74. Zentalis Pharmaceuticals has a twelve month low of $2.66 and a twelve month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. Equities research analysts forecast that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ZNTL. Decheng Capital LLC increased its holdings in Zentalis Pharmaceuticals by 46.2% in the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company's stock valued at $12,558,000 after purchasing an additional 970,859 shares in the last quarter. Verition Fund Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 172.1% in the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock worth $5,536,000 after buying an additional 951,500 shares during the period. Renaissance Technologies LLC grew its stake in shares of Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company's stock valued at $2,706,000 after buying an additional 399,745 shares in the last quarter. GSA Capital Partners LLP raised its holdings in shares of Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company's stock valued at $2,240,000 after buying an additional 353,384 shares during the period. Finally, Primecap Management Co. CA raised its holdings in shares of Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company's stock valued at $5,513,000 after buying an additional 265,690 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.